Inclusion Criteria:

• 1. Subjects aged 18-70 years, both genders.
• 2. Healthy as determined by a physician, based on history, medical examination, vital signs, and laboratory tests.
• 3. Males that agree to use condoms for the duration of participation in the study.
• 4. Females of non-child-bearing potential (i.e., tubal ligation, hysterectomy, or postmenopausal).
• 5. Female patients of child-bearing potential with negative serum pregnancy tests and who agree to use double-barrier contraception during the study.
• 6. Subjects must be able to read, speak, and understand English and/or Spanish and provide written informed consent, and be willing and able to comply with study procedures.
• 7. Subjects must have a BMI 30-35 kg/m2 inclusive assessed immediately prior to screening.
• 8. Fasting insulin level ≥11 mIU/L.
• 9. HbA1c \< 8.5% (diabetic subjects only).
• 10. Subjects with Type 2 diabetes on no anti-diabetic medication or on stable doses of metformin for 4 weeks or more (diabetic cohorts only).
• 11. No history of active or chronic disease other than that allowed by study: hypertension, hyperlipidemia, hyperglycemia, GERD, heartburn, or Type 2 diabetes (cohorts 6 and 7 only).

Exclusion Criteria:

• 1. History of excessive alcohol use (defined as \>21 drinks per week for males and \>14 drinks per week for females), recreational drug use within the past three months, or failure on urinary drug screen.
• 2. Pregnant or breastfeeding within six months of screening assessment.
• 3. Substantial changes in eating habits or exercise routine within the preceding three months.
• 4. Evidence of eating disorders.
• 5. \>5% weight change in the past three months.
• 6. Bariatric surgery within the past five years.
• 7. Significant renal impairment (eGFR \<60 mg/mL/1.73m2).
• 8. Patients on anti-diabetic medications other than metformin.
• 9. Patients with gastroparesis.
• 10. Liver function tests (i.e., ALT, AST, alkaline phosphatase) greater than twice the upper limit of normal upon repeated measurements.
• 11. Diseases interfering with metabolism and/or ingestive behavior (e.g., myxedema, Cushing's disease, schizophrenia, major psychoses).
• 12. History of major depressive disorder within the previous two years, a lifetime history of suicide attempt, suicidal behavior within the previous month, or history of other severe psychiatric disorders.
• 13. Score of \>15 on the Columbia Suicide Severity Rating Scale (C-SSRS).
• 14. Use of medications affecting body weight within the past three months:
• * Drugs approved for the treatment of obesity
• * Cyproheptadine or medroxyprogesterone
• * Atypical anti-psychotic drugs
• * Tricyclic antidepressants
• * Lithium, MAO's, glucocorticoids
• * SSRI's or SNRI's
• * Antiepileptic drugs
• 15. Any clinically significant abnormality following the Investigator's review of the physical examination and clinical laboratory tests.
• 16. A baseline prolongation of QT/QTc interval after repeated measurements of \>450 ms; a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS).
• 17. Participation in an investigational drug trial within the month prior to dosing in the present study.